EU approves new osteoporosis treatment
Amgen and UCB’s Evenity has been given the green light for postmenopausal women with severe osteoporosis to help prevent further fractures
Read More
Tag: Evenity
AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Read More
Amgen’s Evenity FDA approved for osteoporosis in postmenopausal women
One in two women will experience a fracture due to osteoporosis in their lifetime.
Read More
UCB, Amgen refile osteoporosis drug Evenity
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
Read More
UCB, Amgen’s Evenity under review in Europe
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
Read More
US regulators turn away Amgen/UCB’s bone drug Evenity
Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
